COVID-19, impact on myeloma patients

Dufour, Inès; Raedemaeker, Juliette; Andreozzi, Fabio; Verstraete, Géraldine; Bailly, Sarah; Delforge, Michel; Storms, Pauline; Jacquy, Caroline; Velde, Ann Van de; Mineur, Philippe; Lejeune, Marie; Bauwens, Deborah; Obbergh, Florence Van; Kentos, Alain; Nguyen, Janet; Fostier, Karel; Weweire, Anne De; Meuleman, Nathalie; Vekemans, Marie-Christiane

doi:10.1007/s00277-020-04147-7

Cited by 11 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, we report 16 patients with MM who developed COVID-19 infection, 2 with SMM on observation and 14 cases with active MM treated with different regimens, including daratumumab-based combinations in six patients, PI in three, and ImIDs in nine cases. Our report is in agreement with those that showed a higher fatality rate for patients with MM that had developed COVID-19 infection 4,[14][15][16][17] . About 25% of our patients died as a consequence of COVID-19 infection and 10 patients developed COVID-19 pneumonia.…”

Section: Local Experiencesupporting

confidence: 93%

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center

Jiménez-Zepeda¹,

Yau²,

Stewart³

et al. 2022

RIC

View full text Add to dashboard Cite

Background:The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood. Objective: We describe a local experience of the management of MM patients and report their outcomes during the current pandemic. Methods: All consecutive symptomatic MM patients seen at our center since 03/20 were evaluated. Results: A cohort of 156 patients diagnosed from 01/19 to 12/20 was analyzed to interrogate differences in presentation patterns. A total of 553 MM patients were seen and/or treated at Tom Baker Cancer Center in the year of 2020. From those, 47.1% (n = 261) were tested for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Sixteen patients tested positive and data are presented. In addition, a decrease of 21.7% in the rate of new smoldering MM/MM diagnosis was observed in 2020 as compared to 2019. Further, an increase in deaths was also observed in 2020. Conclusions: Our study confirms an increase lethality for MM patients infected with SARS-CoV-2. A balance between safety and need for cancer control should be emphasized. (REV INVEST CLIN. [AHEAD OF PRINT]

show abstract

Section: Local Experiencesupporting

confidence: 93%

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center

Jiménez-Zepeda¹,

Yau²,

Stewart³

et al. 2022

RIC

View full text Add to dashboard Cite

show abstract

“…First, there is the possibility of duplicate patients within studies. We are aware of 2 studies with overlap of 3 patients, 24,33 and 3 studies from centers 20,22,28 that report data to the UKCCMP; thus duplicate patients may potentially have been reported by Lee et al 34 Although it is not known which centers contributed to the ASH registry, the registry was not accepting batch until recently, making overlap between other large aggregate data efforts unlikely (L.K.H., written personal communication, 19 September 2020). Additionally, the majority of studies included were from different centers, different regions, or described differing diagnoses, thus we feel that duplicate reporting is unlikely to be a major factor in our meta-analysis.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Vijenthira

Gong

Fox

et al. 2020

Blood

555

571

View full text Add to dashboard Cite

Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We searched Pubmed and EMBASE up to August 20, 2020, to identify reports of patients with hematologic malignancy and COVID-19. The primary outcome was a pooled mortality estimate, considering all patients and only hospitalized patients. Secondary outcomes included risk of ICU admission and ventilation in hospitalized patients. Subgroup analyses included mortality stratified by age, treatment status, and malignancy subtype. Pooled prevalence, risk ratios (RR), and 95% confidence intervals (CI) were calculated using a random-effects model. 34 adult and 5 pediatric studies (3377 patients) from Asia, Europe, and North America were included (14/34 adult studies included only hospitalized patients). The risk of death amongst adult patients was 34% (95% CI 28-39, N=3240) in this sample of predominantly hospitalized patients. Patients aged >60 years had a significantly higher risk of death than patients <60 years (RR 1.82, 95% CI 1.45-2.27, N=1169). The risk of death in pediatric patients was 4% (95% CI 1-9, N=102). The RR of death comparing patients with recent systemic anti-cancer therapy to no treatment was 1.17 (95% CI 0.83-1.64; N=736). Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying. Patients >60 years have significantly higher mortality, and pediatric patients appear to be relatively spared. Recent cancer treatment does not appear to significantly increase the risk of death.

show abstract

“…Dufour et al recently reported the experience from Belgium in this Journal (published on 23 June 2020), which also demonstrated a high mortality of 35% caused by COVID-19 infection in MM patients, and patients with immigration background especially North-Africans showed the worst survival outcome. However, the majority of the patients who passed away (5/7, 71%) had progressive MM at COVID-19 [9]. In our cohort, the only patient who died was a patient with NDMM receiving frontline therapy, and she showed signs of additional bacterial infection.…”

Section: Dear Editormentioning

confidence: 69%

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan

et al. 2020

View full text Add to dashboard Cite

COVID-19, impact on myeloma patients

Cited by 11 publications

References 4 publications

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center

Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan

Contact Info

Product

Resources

About